Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000560627 | SCV000656813 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2Y | 2022-08-09 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 13 of the TOR1AIP1 protein (p.Glu13Lys). This variant is present in population databases (rs749592068, gnomAD 0.09%). This variant has not been reported in the literature in individuals affected with TOR1AIP1-related conditions. ClinVar contains an entry for this variant (Variation ID: 476284). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV001541470 | SCV001759472 | uncertain significance | not provided | 2024-10-01 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis indicates that this missense variant does not alter protein structure/function |
Genome- |
RCV000560627 | SCV004178525 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2Y | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004678751 | SCV005177863 | uncertain significance | Inborn genetic diseases | 2024-04-01 | criteria provided, single submitter | clinical testing | The c.37G>A (p.E13K) alteration is located in exon 1 (coding exon 1) of the TOR1AIP1 gene. This alteration results from a G to A substitution at nucleotide position 37, causing the glutamic acid (E) at amino acid position 13 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |